MB
REPL icon

MPM BioImpact’s Replimune Group REPL Stock Holding History

MPM BioImpact’s Portfolio REPL Stock Details REPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-983,780
Closed -$9.14M – 48
2025
Q2 		$9.14M Sell
983,780
-3,256
-0.3% -$28.4K 1.58% 30
2025
Q1 		$9.62M Buy
987,036
+37,036
+4% +$458K 1.65% 28
2024
Q4 		$11.5M Buy
+950,000
New +$11.5M 1.63% 29

Other funds holding REPL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

MPM BioImpact's REPL Position: Q3 2025 in Review

MPM BioImpact sold out of Replimune Group (REPL) in Q3 2025, closing a stake of 983,780 shares — an estimated $9.14M sold.

MPM BioImpact first reported a position in REPL in Q4 2024 and held it in 3 quarters. The position peaked at $11.5M in Q4 2024. 163 funds tracked by Wall St. Rank hold REPL as of Q3 2025.

  • MPM BioImpact reported no remaining Replimune Group position as of Q3 2025 after selling out during the quarter.
  • MPM BioImpact sold 983,780 Replimune Group shares in Q3 2025, an estimated $9.14M.
  • MPM BioImpact first reported a position in Replimune Group in Q4 2024 and held it in 3 quarters.
  • MPM BioImpact's Replimune Group position peaked at $11.5M in Q4 2024.
  • 163 funds tracked by Wall St. Rank held Replimune Group as of Q3 2025.

Based on MPM BioImpact's 13F filing for Q3 2025, filed 14 Nov 2025.